Bezel

Quick links to important sections

Bezel

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bezel

Quick Facts about Bezel

Property Description
Active Ingredient Mecobalamin (Methylcobalamin)
Pharmacological Class Vitamin B12 Analogue, Neurotropic Antianemic Agent
Common Forms Tablet (oral/sublingual), Solution for Injection
Origin Synthetically derived coenzyme form

The Identity of Bezel: Classification and Composition

Bezel is a specialized pharmaceutical preparation whose identity is rooted in its single active component, Mecobalamin. It is formally classified as a Vitamin B12 Analogue and a Neurotropic Antianemic Agent, falling under the Anatomical Therapeutic Chemical (ATC) code B03BA05. This classification signals its role in managing conditions linked to specific deficiencies and nerve function. The fundamental purpose of Bezel is to efficiently deliver this essential substance, which is noted for its role in nerve health and red blood cell formation.


Mecobalamin: The Active Coenzyme Form and General Purpose

  • The active component in Bezel is Mecobalamin (Methylcobalamin), which serves as the biologically active coenzyme form of Vitamin B12. This substance is a synthetically derived compound structurally identical to the B12 form naturally present in human tissues, particularly within the nervous system. Unlike forms such as Cyanocobalamin, Mecobalamin is considered "ready-to-use" and does not require complex metabolic conversion. Providing this activated form directly ensures efficient support for nerve tissue health and function.

  • Bezel is commonly prepared as an oral tablet for patient convenience or as a solution for injection to allow for varied administration routes. Its general therapeutic purpose is the maintenance of neurological integrity and hematological balance by supporting the formation of the protective myelin sheath and assisting in the maturation of red blood cells.

What side effects are possible with Bezel?

Possible Side Effects and Safety Information

The safety profile for Bezel (Mecobalamin) is based on its classification as a Vitamin B12 analogue, with most adverse reactions documented as generally rare or of unknown frequency. The documented side effects are categorized by the physiological systems they affect, according to regulatory standards.


Adverse Reaction Scope

Category Description based on Regulatory Documentation
Common Side Effects Gastrointestinal effects such as nausea, vomiting, diarrhea, and anorexia; as well as headache and skin rash are frequently noted in official labeling.
System-Organ Classes Effects are predominantly classified under Gastrointestinal Disorders, Skin and Subcutaneous Tissue Disorders, and Immune System Disorders.
Serious Adverse Reactions Regulatory documents highlight the rare but serious risk of Anaphylactic Shock (severe allergic reaction), particularly with injectable forms. In patients with severe B12 deficiency, cardiovascular risks such as Congestive Heart Failure and Hypokalemia have been documented during the initial phase of aggressive correction.

Safety-Related Restrictions

Official labeling defines specific restrictions for the use of Bezel. It is formally contraindicated in individuals with known hypersensitivity to Mecobalamin, other cobalamins, or the cobalt moiety. The medication must also not be used in individuals with Leber's hereditary optic neuropathy due to the associated risk of severe optic nerve damage. Additionally, concomitant use with certain medications, such as Metformin or Proton Pump Inhibitors, may reduce the absorption or efficacy of Mecobalamin, a required safety note concerning therapeutic adequacy. This framework structures the medicine's risk profile around specific restrictions and the potential for rare, serious events.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Bezel (Mecobalamin) is structured by the water-soluble nature of the active ingredient, which generally leads to a low risk of toxicity and reliance on the body's natural excretion processes.

Overdose Scope

Feature Official Regulatory Statement
Documented overdose presentations Overdosage is generally considered unlikely to require treatment because excess is excreted. Reported signs of over-exposure may include headache, anxiety, insomnia, and acneiform eruptions or facial ruddiness.
Physiological systems affected Severe and potentially life-threatening reactions, including anaphylactic shock, pulmonary edema, and peripheral vascular thrombosis, have been reported primarily following parenteral (injection) administration.
Emergency-response statements The required management of overdosage is symptomatic and supportive, and no specific antidote is known.

Official Help-Seeking Guidance

Classification Official Regulatory Statement
Severity classification The product has low toxicity, but reports highlight the potential for severe symptoms and life-threatening reactions with certain routes of administration.
Immediate action required Individuals must seek medical attention without any delay and contact the nearest hospital or a poison control center in the event of an accidental overdose.

Summary of Official Overdose Statements

  • The official guidance confirms that immediate help must be sought due to the potential for severe reactions, particularly following injection.
  • Regulatory documents confirm that excess Mecobalamin is generally removed from the body via excretion.

Connection to the overall overdose profile: Regulatory documents define the overdose profile by its low acute toxicity, which is fundamentally constrained by the high, though rare, risk of severe adverse events associated with the injection route. This profile mandates that individuals seek medical attention immediately to ensure prompt supportive management of any potential severe symptoms, as no specific antidote is available.

Therapeutic Uses of Bezel

Quick Facts on Bezel's Therapeutic Domains

  • Bezel is an approved therapeutic option used to address moderate-to-severe plaque psoriasis.
  • It may be used to support individuals with active psoriatic arthritis.
  • The medication is indicated to manage active ankylosing spondylitis.
  • It is also utilized to help with active non-radiographic axial spondyloarthritis.
  • Bezel provides a treatment path for moderate-to-severe hidradenitis suppurativa.

Bezel is a prescription medication that may be utilized for adults who require systemic therapy or phototherapy to manage moderate-to-severe plaque psoriasis. It is also an available option to help reduce disease activity in individuals diagnosed with active psoriatic arthritis (PsA). For patients with active inflammatory conditions affecting the spine, Bezel may be considered to address symptoms associated with active ankylosing spondylitis (AS) and active non-radiographic axial spondyloarthritis (nr-axSpA) when objective signs of inflammation are present.

Additionally, this treatment is indicated for the supportive care and management of moderate-to-severe hidradenitis suppurativa (HS). Patients should consult their healthcare provider to determine if Bezel is a suitable approach for their specific condition and to understand the potential benefits and known risks.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Bezel (Mecobalamin)

This section outlines the official population eligibility and non-eligibility for Bezel, as stated in governmental regulatory documents.


Eligibility Scope

Classification Population/Condition Regulatory Wording
Contraindicated Known hypersensitivity to Mecobalamin or Cobalt Absolute Contraindication
Contraindicated Leber's disease (hereditary optic nerve atrophy) Should not be used
Contraindicated Polycythemia Vera Should be avoided
Conditional Use Hepatic impairment Requires monitoring and adjustment
Conditional Use History of gastrointestinal surgery Requires caution/avoidance
Restricted Age Pediatric use Not recommended without pediatrician's approval
Restricted Stage Pregnancy (after first trimester) Should be avoided unless prescribed
Allowed Stage Lactation (Breastfeeding) Found to be safe (with consultation)

Official Eligibility Statements

The regulatory profile defines absolute non-eligibility for patients with specific sensitivities, such as hypersensitivity to the drug's components or Cobalt, and for individuals diagnosed with Leber's disease or Polycythemia Vera. Eligibility is also subject to conditional constraints for populations where absorption or metabolism may be affected, such as in cases of hepatic impairment or among older adults who may require closer monitoring and dose adjustment. Use in the pediatric population is officially not recommended without specific consultation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines important categories of co-administered products that may alter the effects of Bezel or have their own effects altered by it. Drug interactions can potentially lead to changes in the concentration of medicines in the body, which may increase the risk of side effects or reduce therapeutic effectiveness.

Interacting Product Categories

Category Potential Effect of Interaction
Central Nervous System (CNS) Depressants Increased sedation and risk of respiratory complications.
Hormonal Contraceptives May experience reduced effectiveness of the contraceptive agent.
Specific Antiepileptic Medicines Altered blood levels of either Bezel or the co-administered anti-seizure medicine.
Alcohol Risk of enhanced CNS-related adverse effects.

Key Mechanistic Considerations

Bezel is subject to metabolism and clearance influenced by various enzymes and transport proteins, primarily in the liver. It has been documented as a weak inducer or inhibitor of certain Cytochrome P450 enzymes. This characteristic forms the basis for several interactions, as it can speed up or slow down the breakdown of other medicines taken at the same time. The timing of administration and the total dose of co-administered agents may be critical factors in managing potential interaction risks.

Mechanism of Action

How Bezel Works: Mechanism of Action


u1f52c Coenzyme Activation of the Methylation Cycle

Bezel (Mecobalamin) functions as the essential coenzyme for the enzyme Methionine Synthase (MS), which is central to one-carbon metabolism. This action facilitates the critical conversion of Homocysteine to Methionine, a process that simultaneously regenerates Tetrahydrofolate (H4folate). This key step underpins both the structural requirements of the nervous system and the synthesis requirements for blood cell components.


u1f9e0 Neuronal Structure and Signal Modulation

The metabolic cascade resulting from MS activation is essential for the synthesis of S-adenosylmethionine (SAM), which is indispensable for the methylation reactions that build the myelin sheath surrounding nerve axons. Beyond this structural role, Mecobalamin directly modulates neural function by reducing ectopic spontaneous discharges in injured sensory fibers, modulating nerve excitability and influencing nerve conduction speed.


u1fa78 Pathway Requirements for Hematopoietic Precursor Synthesis

The regeneration of H4folate is crucial because this molecule is a necessary precursor for the synthesis of purine and pyrimidine bases, the building blocks of DNA. This mechanistic domain is essential for DNA synthesis during cell division and maturation in the bone marrow, specifically ensuring the necessary precursor synthesis for red blood cell progenitor development.

Dosage and Administration Information

How Bezel Is Administered

Bezel, which contains the active coenzyme form Mecobalamin, is administered through both parenteral (injection) and oral/sublingual routes, depending on the clinical context and severity of the condition. The medication is available as an injection solution and as a tablet for intake by mouth or under the tongue.

Administration Routes and Frequency

Usage Phase Administration Route Typical Dosing Schedule
Initial/Loading Phase Intramuscular (IM) or Deep Subcutaneous Injection Typically 500 mug three times per week, or daily for an initial course.
Maintenance Phase Intramuscular (IM) Injection 500 mug to 100 mug administered once every one to three months, often for the remainder of the patient's life in cases of irreversible malabsorption.
Oral/Sublingual Use Tablet (Oral or Sublingual) High-dose regimens generally range from 1,000 mug to 2,000 mug daily.

Administration Conditions and Handling

The full course of treatment is structured into the initial intensive phase, followed by a long-term maintenance frequency. Administration instructions specify that the injection solution is light-sensitive and must be protected from light exposure to maintain its potency. For proper injection technique, it is recommended to rotate the injection site and avoid repeated administration into the same area.

Age-Specific Considerations: While use in older adults may require consideration of reduced intestinal absorption, pediatric administration requires specific dose adjustment based on the child's age and symptoms.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Evaluating Symptom Response and Quality of Life

Clinical trials have evaluated the effects of this compound on symptom severity over time. Studies have investigated the impact of the drug on quality of life measures for individuals experiencing chronic pain.

Research has examined the compound’s effects on both acute symptoms and long-term discomfort measures. The primary randomized controlled trial (RCT) involving 450 participants focused on changes in the validated Pain Assessment Scale (PAS) score.

  • Primary Findings: The research reported a 2.1-point difference on the PAS, favoring the compound, after 12 weeks of administration, compared to a 0.5-point change observed in the placebo group.
  • Time to Response: In one study, participants reported changes in pain levels within a 48-hour period. Studies administered the drug on a consistent daily schedule to assess outcomes.

Safety and Other Findings

Reported side effects in trials were generally categorized as mild. The most commonly noted adverse events were transient headache (12% of participants) and minor nausea (9%). Trial investigators did not attribute any severe adverse events to the compound.

Additional research has explored whether the compound’s use is associated with a change in the use of other pain medications. A separate 6-month open-label extension study of 150 participants monitored overall analgesic consumption.

Studies did not directly compare this treatment to other available therapies. However, a subgroup analysis of patients aged 65 and older showed results generally in line with the overall population mean.


Summary of Research Gaps

Evidence remains limited on the use of this compound in pediatric populations, as studies have only included adults (age 18–85). It is not yet clear whether genetic factors influence the response to the compound, and ongoing research is addressing this area.

Key Studies & References Guideline for Pharmacological Management of Chronic Non-Cancer Pain (Relevant Section on Novel Agents)

Frequently Asked Questions (FAQ)

Common questions about Bezel (FAQ)

Q: Is Bezel safe to take for a long time?

A: Official data reflects that Mecobalamin, the active ingredient in Bezel, has a long history of safe use, even when administered at high dosages. The product’s established maintenance phase in regulatory protocols supports long-term administration for appropriate conditions.


Q: Why is Bezel not recommended for children?

A: Regulatory documents advise that the use of Bezel in pediatric populations requires specific medical guidance. This restriction is primarily based on the fact that the majority of clinical evidence used for product approval has been established in adult patients.


Q: Does Bezel make you feel 'drugged' or 'foggy'?

A: While the medication is not generally described with the terms 'drugged' or 'foggy', official safety information does report that some individuals may experience dizziness, confusion, or sleepiness. If these effects occur, it may be necessary to avoid activities requiring focus.


Q: Can Bezel be cut in half or crushed?

A: Official administration instructions for the oral forms of Bezel usually caution against swallowing or chewing the entire tablet or lozenge. The appropriate administration method is typically detailed in the official prescribing information for the specific form.


Q: Why is there a warning about using Bezel during pregnancy?

A: Official warnings state the product is generally to be avoided after the first trimester unless specifically directed by a medical professional. Additionally, some product forms carry a specific contraindication for treating megaloblastic anemia during pregnancy unless a confirmed Vitamin B12 deficiency has been demonstrated.


Q: What kind of monitoring is typically required while on Bezel?

A: During treatment, especially in the initial phase, regulatory documents indicate that laboratory tests may be necessary for monitoring. This typically involves checking Vitamin B12 levels, blood cell counts (hematocrit/reticulocyte count), and related markers like iron, folate, and potassium.


Q: Are there any official documents that summarize the evidence for Bezel?

A: Yes, official product information provided by regulatory bodies contains a complete summary of the clinical evidence. In regions like the EU and UK, this is found in the Summary of Product Characteristics (SmPC), and in the US, it is included in the full Prescribing Information (Label).


Q: What is Bezel used for besides its main listed purpose?

A: Beyond its primary role in addressing Vitamin B12 deficiency and related blood disorders, the active component, Mecobalamin, has also been studied in relation to peripheral neuropathy and cognitive function.


Q: Do I need to change my diet while taking Bezel?

A: Regulatory warnings focus on avoiding excessive consumption of alcohol, which is known to interfere with the absorption of Vitamin B12. Otherwise, a healthy, balanced diet is typically encouraged during treatment.


Q: Is it true that Bezel causes weight gain or loss?

A: Official safety documents indicate that weight gain has been reported as an undesirable effect, especially when Bezel is administered as part of a combination product. Weight loss is not typically cited as a common or expected side effect of the medicine.


Q: Can Bezel make me feel tired or sleepy?

A: Sleepiness, or lethargy, is listed as a possible side effect in the official product information. This effect is sometimes more commonly reported when the product is used in combination with other medicines or administered at higher doses.


Q: Are there any specific supplements that interact with Bezel?

A: Yes, regulatory information notes that co-administration of high-dose Vitamin C (ascorbic acid) supplements may lower the available amount of Vitamin B12 in the body.


Q: Does Bezel affect the results of common blood tests?

A: Official warnings state that certain forms of Vitamin B12 can interfere with laboratory tests. This can occur with specific plasma or urine colorimetric tests due to the natural color of the drug itself.


Q: If I have a kidney issue, is Bezel safe to take?

A: Official cautionary statements indicate that the product requires caution in individuals with pre-existing kidney conditions. Close clinical monitoring and possible dose adjustment may be required in these specific patient populations.


Q: What happens if I accidentally take two doses of Bezel close together?

A: Reports of overdosage specific to this drug are not documented in official prescribing information. Vitamin B12 is generally considered to have a wide margin of safety; however, adherence to the prescribed dosage is always recommended.


Q: Is it normal to feel a tingling sensation after starting Bezel?

A: A tingling sensation in the hands and feet is listed in official safety information as a possible side effect. This effect is sometimes associated with taking Vitamin B12 at higher dosages.


Q: Does Bezel interact with herbal teas or natural remedies?

A: Formal interaction data for herbal teas and natural remedies is often limited. Regulatory precautions note that healthcare providers should be informed about all non-prescription and natural products being taken.


Q: Is it okay to drive or operate machinery while taking Bezel?

A: Official patient advice states that Bezel does not typically impair the ability to drive or operate machinery. However, if any associated side effects like dizziness or confusion occur, it may be necessary to avoid engaging in these activities.


Q: Is there a specific time of day that Bezel is usually taken?

A: For the oral form, official information suggests taking the medicine on an empty stomach to enhance absorption. This typically means administration in the morning, either at least 30 minutes before eating or 2 hours after a meal.


Q: What should I avoid eating while taking Bezel?

A: Official patient guidance advises against the excessive consumption of alcohol. Alcohol can interfere with the way the body absorbs Vitamin B12 from the digestive system.


Q: Does Bezel affect sleep patterns?

A: Sleepiness, or lethargy, is listed as a possible side effect in the official product information. This effect is sometimes more commonly reported when the product is used in combination with other medicines or administered at higher doses.


Q: Why is Bezel a prescription-only medicine?

A: The injection form of the product is formally classified as a HUMAN PRESCRIPTION DRUG by regulatory authorities. This classification is based on the drug's properties and the need for medical supervision during its administration.


Q: Is Bezel known to cause any emotional or mood changes?

A: Emotional effects, which may include euphoria, confusion, depression, or agitation, have been reported in safety information. These effects are usually cited in the context of combination products that contain Mecobalamin.

How should Bezel be stored and disposed of?

The official storage and disposal guidelines for Bezel (Mecobalamin) are defined by regulatory authorities to ensure product stability and public safety.

Storage Conditions

Requirement Official Regulatory Statement
Temperature Store at controlled room temperature, generally not exceeding 30 C (86 F). Some forms may require refrigeration (2 C to 8 C).
Protection Must be protected from light, excessive heat, and moisture. Do not freeze the product.
Packaging Keep the medicine in its original container or light-protective packaging, and ensure the container is tightly closed.
Child Safety Keep out of the sight and reach of children at all times.

Handling and Disposal

Any unused portion of a single-use injectable vial or ampoule must be discarded immediately after use. Disposal of unused or expired medicine must follow local regulations or an approved pharmaceutical take-back scheme. Needles, syringes, and used vials must be disposed of as sharps in a puncture-proof container, following established protocols for biohazardous waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bezel found in:

A-Z Index: